RxDoctor Payments Data

Theodore Seger, MD

Family Medicine · Indianapolis, INNPI 1598146565

Payments from drug & device makers

$586in general payments, 2019–2025

Across 42 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • GSK$94
  • Amgen$64
  • Boehringer Ingelheim$64
  • AstraZeneca$49
  • Merck$46
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$53892%
  • Education$488%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$586 in reported general payments places this provider in the 50th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$54,760
Medicare patients
155
Services billed
3,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$126,091
EliquisApixaban42$60,462
TrulicityDulaglutide31$57,955
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$34,826
JardianceEmpagliflozin19$28,266
MounjaroTirzepatide25$26,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,036
XareltoRivaroxaban11$17,842
Aimovig AutoinjectorErenumab-Aooe17$12,552
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$11,616
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$7,699
Varenicline Tartrate19$5,230
Atorvastatin Calcium510$3,718
Gabapentin182$3,312
Omeprazole206$3,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$111$126,09182 claims
Lilly USA, LLCTrulicity, Mounjaro$26$84,85356 claims
GSKAnoro Ellipta, Trelegy Ellipta$94$53,86158 claims
Boehringer IngelheimJardiance, Stiolto Respimat$64$39,88234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →